Compare
Acrivon Therapeutics, Inc. vs Silence Therapeutics plc vs Zomedica Corp. vs Seres Therapeutics, Inc.
| Latest fiscal year | Acrivon Therapeutics, Inc. ACRV | Silence Therapeutics plc SLN | Zomedica Corp. ZOMDF | Seres Therapeutics, Inc. MCRBRevenue covers only part of its income (partial revenue) |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $559.0K | $32.03M | n/a |
| Revenue growth (YoY) | n/a | -98.7% | +17.4% | n/a |
| Gross margin | n/a | 61.5% | 67.7% | n/a |
| Operating margin | n/a | n/m | -263.4% | n/a |
| Net margin | n/a | n/m | -255.6% | n/a |
| Net income | -$77.91M | -$88.61M | -$81.86M | $5.70M |
| EPS (Diluted) | -$2.02 | -$0.63 | -$0.08 | $0.64 |
| Operating cash flow | -$63.66M | -$62.27M | -$17.65M | $1.12M |
| Free cash flow | -$65.33M | -$62.33M | -$18.22M | $865.0K |
| Cash & equivalents | $41.50M | $11.28M | $9.02M | $45.77M |
| Total assets | $129.72M | $131.44M | $127.04M | $138.19M |
| Total liabilities | $17.20M | $69.14M | $11.64M | $93.97M |
| Shareholders' equity | $112.52M | $62.30M | $115.40M | $44.22M |
| Return on year-end equity | -69.2% | -142.2% | -70.9% | 12.9% |
| Shares outstanding | 31.65M | 141.70M | 979.95M | 9.56M |
Revenue, most recent five fiscal years
| Fiscal year | Acrivon Therapeutics, Inc. | Silence Therapeutics plc | Zomedica Corp. | Seres Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $559.0K Ended 2025-12-31 | $32.03M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $43.26M Ended 2024-12-31 | $27.29M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $31.64M Ended 2023-12-31 | $25.19M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $21.66M Ended 2022-12-31 | $18.93M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $4.13M Ended 2021-12-31 | n/a |